Recon: Lilly's obesity pill reduced weight, blood sugar in late-stage trial; EU approves Gilead’s HIV PREP injection

• HHS terminates NIH program aimed at diversifying biomedical workforce (STAT)
• BARDA awards nearly $20M to flu vaccine maker Osivax, following mRNA pullback (Endpoints)
• Overall survival in cancer drug trials: New FDA draft guidance sets the bar (Endpoints)
• Somewhere in Time: FDA Releases Its FY 2024 Report on Pharma Quality As Industry Looks to 2026 (FDA Law Blog)
• Trump and RFK Jr. to Ban COVID-19 Vaccine ‘Within Months’ (Daily Beast) (Newsweek)

• Top pharma companies work to launch first weight-loss pill (Reuters)
• EU approves Gilead's new injection for preventing HIV (Reuters)
• Bayer is charting $43M in upgrades to API plant in Mexico (Fierce Pharma)
• Mubadala-Backed Ignis Therapeutics Is Said to Mull Hong Kong IPO (Bloomberg)
• Bavarian Bidders Lower Takeover Threshold After Pushback (Bloomberg)

• Illumina CEO sees path to stable growth, even as its academic customers face funding uncertainty (STAT)
• Eli Lilly’s obesity pill helped lower weight, blood sugar in key Phase 3 trial (STAT)
• Generic Industry Looking For Expanded Inspections As US FDA Rehires Staff (Pink Sheet)
• Regeneron's rare immune disorder therapy meets main goal of late-stage trial (Reuters)
• Exclusive: Neuro startup Leal raises $30M Series A for schizophrenia and ALS trials (Endpoints)
• Why former Walmart Health head Cheryl Pegus joined weight loss startup FlyteHealth (Endpoints)
• Pfizer lays off 100 workers at former Seagen HQ (Fierce Pharma)
• Health-Care Deal Creates $6 Billion Company Aiming to Upend Drug Middlemen (Bloomberg)
• Thomson Medical Jumps 39% on New Project in Johor Special Zone (Bloomberg)
• Interactive Brokers Climbs on Replacing Walgreens in S&P 500 (Bloomberg)
• Good News on GLP-1s and Cancer Risk, With One Exception (MedPage Today)

• Terumo to buy OrganOx for $1.5B to enter transplant field (MedTech Dive)
• Tempus inks $81M Paige buyout to support AI model development (MedTech Dive)
• Study Finds Public Companies Behind Most Recalled AI Devices (MedTech Insight)
• Reports Put $4B Price Tag On Versius Maker CMR. Will This Change Surgical Robot Valuation? (MedTech Insight)

• Kraft, other companies defeat test lawsuit over ultra-processed foods (Reuters)
• Radioactive shrimp and rodent-infested warehouses: Why food recalls still shock us (Food Safety News)
• Alzheimer's Genetic Risk May Be Effectively Countered With Diet (MedPage Today)

• We surveyed hundreds of biomedical researchers about the instability in federal funding. Here’s what they said (STAT)
• HHS winds down pediatric brain tumor pact after 26 years, prioritizing other childhood cancer work (Endpoints)
• Private-Equity Firm Said to Prioritize Profit Over Patients (Bloomberg)